Brian Culley
Chief Executive Officer at LINEAGE CELL THERAPEUTICS, INC.
Net worth: 171 875 $ as of 29/04/2024
Network origin in Brian Culley first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
University of California, Berkeley
222
| College/University | Other Consumer Services | 222 |
Mast Therapeutics, Inc.
 Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA.
35
| Extinct | Pharmaceuticals: Major | 35 |
| Public Company | Biotechnology | 29 | |
| Subsidiary | Biotechnology | 11 | |
iTherX Pharmaceuticals, Inc.
 iTherX Pharmaceuticals, Inc. Medical DistributorsDistribution Services iTherX is a clinical stage pharmaceutical company focused on the discovery and development of innovative treatments for Hepatitis C. This is a disease that affects almost 3% of the world's population, and is the major cause of chronic liver disease, cirrhosis, liver failure and primary liver cancer. Currently there is only a single mode of therapy and less than 5% of patients can be successfully treated. The company continues to carry out focused research in their areas of expertise to provide sustainability of product pipelines. In an era of managed care and increased regulatory scrutiny, it is easy to yield to the temptation of producing 'me too drugs'. However, they think that innovation in the development of pharmaceutical products is important because it is the only way to improve the outcomes for patients. As such, they also think that innovation can ensure the financial returns that investors in health care deserve for the risks that they take. Their innovative approach is evident in their pipeline of Hepatitis C drug candidates. As new and better treatments are being sought, most companies involved in this effort are targeting the enzymes responsible for viral replication: polymerases and proteases. While these are important targets, there is a great deal of duplication of effort in these initiatives. At iTherX, they are pioneering the development of a novel class of HCV antivirals by targeting the steps involved in the entry of the hepatitis C virus into liver cells. Their Host Cell Receptor Target Program engenders small molecule compounds that target a liver cell membrane protein, SR-B1, which recognize and dock the virus. Their lead compound, ITX5061, has extensive safety data in over 250 patients, and shows picomolar potency in inhibiting HCV infection in vitro. They plan to initiate a Phase 2a clinical trial in HCV patients in Q2 of 2009. They have also used medicinal chemistry to develop back-up compounds for this program, and a clinical candidate has been selected for development. Another innovative program is novel cell receptor, which develops antagonists (including biologics) against a novel liver cell membrane protein required for infectivity of the virus.
2
| Extinct | Medical Distributors | 2 |
| Public Company | Pharmaceuticals: Major | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Brian Culley via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| HP INC. | Computer Processing Hardware | Corporate Officer/Principal Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Private Equity Investor Corporate Officer/Principal Corporate Officer/Principal | |
| STAAR SURGICAL COMPANY | Medical Specialties | Director of Finance/CFO Chairman Director/Board Member | |
| LIFEVANTAGE CORPORATION | Pharmaceuticals: Other | Director of Finance/CFO Public Communications Contact | |
| QUESTCOR PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member Chief Operating Officer Chief Executive Officer Director/Board Member Director/Board Member Director of Finance/CFO Chief Tech/Sci/R&D Officer | |
| JPMORGAN CHASE & CO. | Major Banks | Corporate Officer/Principal Corporate Officer/Principal | |
Epitomics, Inc.
 Epitomics, Inc. Pharmaceuticals: MajorHealth Technology Epitomics, Inc. an emerging biotechnology company, is dedicated to developing their breakthrough monoclonal antibody technology (RabMAb®) for research, diagnostics and therapeutics. The Company has utilized a unique and proprietary RabMAb technology invented by scientists at Loyola University of Chicago and the University of California at San Francisco. This enabling platform produces high quality antibodies that have the potetial to be used in the broad areas of research, diagnostics and therapeutics. Compared to currently available monoclonal antibody technology, such as mouse hybridomas, the company's proprietary technology can generate RabMAbs more efficiently and with superior binding affinity and bioactivity in a wide variety of biological assays. The high throughput and robust nature of the technology allows for the simultaneous discovery of disease targets and potential therapeutic antibodies in the same experiments, significantly shortening the drug discovery and development cycle. The company aims to become the largest provider of monoclonal antibody technology through developing and commercializing their RabMAb technology and products in research, diagnostics, and therapeutics. The firm is headquartered in Burlingame, California and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
Elan Pharmaceuticals, LLC
 Elan Pharmaceuticals, LLC Pharmaceuticals: MajorHealth Technology Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA. | Pharmaceuticals: Major | Sales & Marketing Chief Tech/Sci/R&D Officer | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
| SHIRE | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
ReCyte Therapeutics, Inc.
 ReCyte Therapeutics, Inc. BiotechnologyHealth Technology ReCyte Therapeutics, Inc. operates as a regenerative medicine company. It focuses on repair of vascular disorders, including both age-related diseases and injuries. The company was founded in January 2011 and is headquartered in Alameda, CA. | Biotechnology | Chief Executive Officer Director/Board Member | |
| MALLINCKRODT PLC | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member Chairman General Counsel | |
| TURG POIN | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| The Trustees of Columbia University in The City of New York | College/University | Graduate Degree Graduate Degree | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| Stanford University | College/University | Masters Business Admin Undergraduate Degree Undergraduate Degree Doctorate Degree Undergraduate Degree Masters Business Admin Doctorate Degree | |
| George Washington University | College/University | Undergraduate Degree Graduate Degree | |
University of Southern California
 University of Southern California Other Consumer ServicesConsumer Services University of Southern California is a private research university that mainly offers undergraduate, graduate & other higher education. The university was founded in 1880 and is headquartered in Los Angeles, CA. | College/University | Graduate Degree Masters Business Admin Graduate Degree | |
Merriman Capital, Inc.
 Merriman Capital, Inc. Investment Banks/BrokersFinance Founded in 1986, Merriman Capital, Inc. is an SEC-registered broker/dealer and investment banking firm headquartered in San Francisco. The firm is a subsidiary of Merriman Holdings, Inc. (NASDAQ: MERR), a financial services firm that focuses on fast-growing companies and their institutional investors. Merriman provides advisory and investment banking, equity research, institutional services, corporate services and venture services primarily to corporate clients. Merriman Capital provides research, brokerage and trading services primarily to institutional clients. The firm offers a full range of specialized and integrated services including: equity research, specialized trade execution, equity capital markets, corporate finance, mergers and acquisitions, sales and trading, market making, corporate and venture services, restructurings and strategic advisory services. Merriman Capital employs bottom-up, fundamental analysis of small-cap companies in select industries including clean technology, healthcare, technology and consumer/Internet/media. The firm also has expertise in emerging markets, with emphasis on emerging markets in China. Merriman Capital is known to engage in shareholder activist investment strategies. Merriman Capital is a member of the NASD, the SIPC and FINRA. The firm serves as an introducing broker/dealer for Pershing LLC. They do not hold or maintain funds or securities or provide clearing services for other broker/dealers. | Investment Banks/Brokers | Director/Board Member Corporate Officer/Principal | |
| San Diego State University | College/University | Masters Business Admin Undergraduate Degree Undergraduate Degree | |
| Rutgers State University of New Jersey | College/University | Undergraduate Degree Undergraduate Degree | |
| The University of Chicago | College/University | Undergraduate Degree Masters Business Admin | |
| Lehigh University | College/University | Graduate Degree Undergraduate Degree | |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | College/University | Graduate Degree Undergraduate Degree | |
| New York University | College/University | Undergraduate Degree Masters Business Admin | |
| Santa Clara University | College/University | Masters Business Admin Undergraduate Degree Graduate Degree | |
| University of Wisconsin | College/University | Doctorate Degree Doctorate Degree | |
| University of California, Davis | College/University | Undergraduate Degree Undergraduate Degree | |
| University of California San Diego | College/University | Undergraduate Degree Undergraduate Degree Corporate Officer/Principal | |
| University of Maryland | College/University | Corporate Officer/Principal Undergraduate Degree | |
| University of Michigan | College/University | Masters Business Admin Corporate Officer/Principal | |
RBC Capital Markets LLC
 RBC Capital Markets LLC Investment Banks/BrokersFinance RBC Capital Markets LLC is a full-service brokerage and financial services firm headquartered in New York City. They are a direct subsidiary of RBC USA Holdco Corp. and a wholly-owned indirect subsidiary of Royal Bank of Canada (TSE, NYSE: RY). Founded in 2010, the firm is comprised of 3 major business lines: the Private Client Group, the Fixed-Income Group and the Clearing and Execution Services Group. The Private Client Group serves individual investors, while the Fixed-Income Group provides services to institutions, municipalities and non-profit organizations. The Clearing and Execution Services Group is a provider of clearing and execution services to independent brokers/dealers throughout the US. RBC Capital Markets focuses on the following sectors: communications, media, consumer/retail, diversified industries, energy, financial institutions, forest products, healthcare, infrastructure finance, mining & metals, real estate, social infrastructure, technology and the US municipal markets. | Investment Banks/Brokers | Corporate Officer/Principal Corporate Officer/Principal | |
| ONCOCYTE CORPORATION | Biotechnology | Corporate Secretary Director/Board Member Director of Finance/CFO Chairman Director/Board Member Chairman Chairman Director/Board Member | |
| SAVARA INC. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO Director/Board Member Director/Board Member Investor Relations Contact General Counsel | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
| BIORA THERAPEUTICS, INC. | Medical/Nursing Services | Chief Executive Officer Director/Board Member | |
Cell Cure Neurosciences Ltd.
 Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | Biotechnology | Chairman Director/Board Member | |
The Column Group LLC
 The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Investment Managers | Private Equity Investor Private Equity Investor | |
| University of Science & Technology of China | College/University | Undergraduate Degree Undergraduate Degree | |
| New York University School of Medicine | College/University | Corporate Officer/Principal Graduate Degree | |
| University of San Diego | College/University | Masters Business Admin Masters Business Admin | |
Cooley LLP
 Cooley LLP Miscellaneous Commercial ServicesCommercial Services Cooley LLP engages in the provision of legal services. It offers strategic litigation and business transaction services and is a representative of private and public companies, financial institutions, venture capital firms and nonprofit organizations. Its practices include commercial litigation; patent counseling and prosecution; employment and labor; asset recovery; and estate planning and personal representation. The company was founded in 1920 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Ascendance Biotechnology, Inc.
 Ascendance Biotechnology, Inc. BiotechnologyHealth Technology Ascendance Biotechnology, Inc. engages in the sale of cell-based assay products. It offers Hepregen and ESI Bio. The firm also offers stem cell technology. The company was founded by Vincent R. Zurawski, Jr. and Jeffrey D. Janus is headquartered in Alameda, CA. | Biotechnology | Director/Board Member Director/Board Member |
Statistics
International
| United States | 40 |
| Ireland | 3 |
| Mauritius | 2 |
| France | 2 |
| Israel | 2 |
Sectoral
| Consumer Services | 22 |
| Health Technology | 16 |
| Finance | 5 |
| Commercial Services | 3 |
| Communications | 2 |
Operational
| Director/Board Member | 315 |
| Corporate Officer/Principal | 211 |
| Undergraduate Degree | 94 |
| Independent Dir/Board Member | 85 |
| Chief Executive Officer | 61 |
Most connected contacts
| Insiders | |
|---|---|
| Eric Rowinsky | 36 |
| Anula Kusum Jayasuriya | 31 |
| Ted Love | 31 |
| Peter Greenleaf | 31 |
| Dominic Ang | 25 |
| Andy Arno | 25 |
| Lewis J. Shuster | 23 |
| Michael West | 21 |
| Evan Levine | 20 |
| Nickhil Jakatdar | 18 |
| Timothy Kutzkey | 18 |
| Russell Skibsted | 17 |
| Howard C. Dittrich | 17 |
| Michael Franklin | 16 |
| Alfred Kingsley | 16 |
- Stock Market
- Insiders
- Brian Culley
- Company connections
